The @entity21900 @entity5 suppressor gene, which encompasses the fragile site @entity21900 at 3p14.2, is altered frequently in many types of @entity1 @entity5 . To determine its importance as a prognostic marker in @entity0 , the expression of the @entity21900 protein was studied in a series of 452 @entity0 by using immunohistochemistry on sections of tissue microarrays. Three distinct levels of @entity21900 expression were observed: in 154 cases (34.1%) expression was unchanged as compared to normal level; in 78 (17.2%) no expression was found; in the remaining 220 cases (48.7%), expression was intermediate. Overall, two-thirds of the cases had abnormal levels of the protein. Absence of @entity21900 was significantly associated with a higher grade (p < 0.01) and absence of hormone receptors (p < 0.001). The @entity1 were separated into Group I (153 node-negative good prognosis @entity1 who did not receive adjuvant chemotherapy) and Group II (226 high-risk @entity1 treated by adjuvant chemotherapy) according to the St.-Gallen conference consensus. The median follow-up was 48 months. Among Group I but not Group II @entity1 , a multivariate analysis showed that @entity21900 expression was significantly associated with disease-free survival. The relative risk of recurrence for @entity21900 -negative Group I @entity1 was 2.37 (1.21-4.64; p = 0.03). Thus, among the @entity1 who present with @entity5 of apparent good prognosis, @entity21900 is an independent prognostic factor that distinguishes a subgroup of @entity1 who could benefit from adjuvant treatment.

Loss of XXXX protein expression is a marker of adverse evolution in good prognosis localized @entity0 .

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'tumors'] @entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity21900 :: ('2272', 'Gene') :: ['FRA3B', 'FHIT'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'breast carcinomas']
@entity21900 :: (2272,Gene) :: ['FHIT']
